Polyguard Drugs

Ayurvedic healthcare products manufacturing and distribution in India.

About Polyguard Drugs

Polyguard Drugs is a Healthcare company. Ayurvedic healthcare products manufacturing and distribution in India. Its Indian entity Polyguard Drugs Private Limited reported revenue of β‚Ή62.9 Lakh. Polyguard Drugs offers products and services including Eminogard Capsule and Betacore Syrup. Its focus areas include Health and Pharmaceuticals, Manufacturing, Herbal Products and Laboratory Processing.

Company details

Polyguard Drugs is recognized for supplying standardized Ayurvedic products that address modern health challenges through natural remedies, as supported by research at their laboratories. These products, including capsules and syrups, are formulated to tackle issues like diabetes and arthritis without side effects, drawing from ancient Ayurvedic principles. The company maintains high-quality standards with certifications like WHO-GMP and operates from locations in India, emphasizing balance in health and wellness through carefully selected ingredients. A focus on accessibility ensures these offerings reach those seeking natural alternatives.

Key Metrics
  • Indian entity revenue
    ₹62.9 Lakh

    FY 2025 · +15% YoY

  • Indian entity net loss
    -₹20,050

    FY 2025 · 0% margin

  • Indian entity EBITDA
    ₹3 Lakh

    FY 2025 · 5% margin

Products & Services of Polyguard Drugs

Polyguard Drugs offers a comprehensive portfolio of products and services, including Eminogard Capsule and Betacore Syrup.

Eminogard Capsule
Ayurvedic Capsules

Ayurvedic capsules are provided for health support, drawing from natural formulations

Betacore Syrup
Ayurvedic Syrups

Syrups are offered for various health needs, based on herbal ingredients

Board of directors of Polyguard Drugs Private Limited (Polyguard Drugs)

Polyguard Drugs Private Limited is the primary company behind Polyguard Drugs. The board of Polyguard Drugs Private Limited currently have 3 directors; the longest-serving is Anjali Jaiswal, appointed in 1999.

DirectorDesignationAppointedTenureEntity
Anjali Jaiswal
DIN 00682971
Director11 Feb 199927 yrs 9 moPolyguard Drugs Private Limited
Roy Saheb Jaiswal
DIN 00683002
Director11 Feb 199927 yrs 9 moPolyguard Drugs Private Limited
Pratyaksh Jaiswal
DIN 08630919
Director02 Dec 20196 yrs 11 moPolyguard Drugs Private Limited

Financials of Polyguard Drugs

Figures of Polyguard Drugs Private Limited, the primary company behind Polyguard Drugs, for FY 2025. Revenue was ₹62.9 Lakh (+15% year on year). Net loss was -₹20,050 (0% margin). EBITDA was ₹3 Lakh (5% margin). Revenue has grown at a compounded annual rate of +15% over three years and +4% over five years.

  • ₹62.9 LakhRevenue · FY 2025 · +15% YoY
  • -₹20,050Net loss · 0% margin
  • ₹3 LakhEBITDA · 5% margin
  • ₹5 LakhPaid-up capital
  • +15%Revenue CAGR, 3 years
  • +4%Revenue CAGR, 5 years

Balance sheet, profit and loss, cash flow and ratios of Polyguard Drugs Private Limited are on its company page.

Premium access

Detailed financial statements for Polyguard Drugs

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Frequently Asked Questions about Polyguard Drugs

The primary company behind Polyguard Drugs, Polyguard Drugs Private Limited, reported revenue of β‚Ή62.9 Lakh for FY 2025, up 15% year on year.

Polyguard Drugs is recognized for supplying standardized Ayurvedic products that address modern health challenges through natural remedies, as supported by research at their laboratories. These products, including capsules and syrups, are formulated to tackle issues like diabetes and arthritis without side effects, drawing from ancient Ayurvedic principles. The company maintains high-quality standards with certifications like WHO-GMP and operates from locations in India, emphasizing balance in health and wellness through carefully selected ingredients. A focus on accessibility ensures these offerings reach those seeking natural alternatives.

Polyguard Drugs offers Eminogard Capsule and Betacore Syrup.

Polyguard Drugs operates through Polyguard Drugs Private Limited.

The legal entities of Polyguard Drugs currently have 3 directors, including Anjali Jaiswal, Roy Saheb Jaiswal, Pratyaksh Jaiswal.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available